Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Benzinga

By Meg Flippin, Benzinga A decade after a deadly ebola outbreak that left more than 11,000 people dead and only six years after another outbreak killed over 2,000, more needs to be done to find an effective treatment for this infectious disease. That’s what RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company, is seeking to do with its novel, potentially broad-acting, host-directed therapy, opaganib, a first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity. The U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), just selected opaganib for further development to treat exposure to Ebola virus disease (EBOV). To date, RedHill Biopharma said opaganib has made positive progress on the expected Animal Rule pathway towards potential approval as a treatment for EBOV. The Animal Rule allows for the use of pivotal animal model efficacy studies to support the U.S. Food and Drug Administration’s (FDA) approval of new drugs when human clinical trials are not ethical or feasible. New Treatments Needed Ebola is a rare and often deadly virus caused by infection by one of a group of four viruses known as ebolaviruses. Transmission of the disease is mostly through contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with an ebolavirus. Currently, only Inmazeb, a combination of three monoclonal antibodies and Ebanga, a single monoclonal antibody, are FDA-approved to treat EBOV. Both are intravenously administered. According to RedHill Biopharma, there is an urgent need for host-directed small molecule therapies that may be effective against multiple strains of ebolavirus, are less likely to be impacted by viral mutation and are easy to store, distribute and administer, especially in areas where healthcare services and infrastructures may be sub-optimal. With ebola cases predicted to grow in the years to come, driven by a lack of effective treatment, so is the market size for vaccines and treatments. According to one forecast, the ebola drug and vaccine market is poised to reach $223.7 million by 2027, growing at a CAGR of 12.8% from 2022 to 2027. Opaganib, which is orally administered, is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis and the disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS). BARDA To Provide Funding Under the cost-sharing agreement with BARDA, BARDA will provide funding to further advance opaganib to mitigate infections and contain EBOV outbreaks. In an in vivo EBOV study with the United States Army Medical Research Institute of Infectious Diseases, RedHill Biopharma said opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day. RedHill Biopharma said it’s the first host-directed molecule to show activity in EBOV. What’s more, RedHill said opaganib also recently demonstrated a distinct synergistic effect when combined individually with the COVID-19 antiviral treatment remdesivir, significantly improving potency while maintaining cell viability. “EBOV is deadly, killing, on average, half of all those who contract it. This year marks ten years since the West Africa Ebola epidemic in which 11,000 people died, and yet there are still no host-directed, small molecule therapies approved to provide effective and usable treatment strategies,” said Guy Goldberg, RedHill’s Chief Business Officer. “There are also enormous geopolitical and logistical challenges to overcome in managing outbreaks such as EBOV, and others like Mpox, and so new host-directed, small-molecule therapeutic options for biodefense and global health preparedness could prove to be major life-saving advances – this is especially true if they are capable of viral mutation-resistance, have extended shelf-lives for long-term storage, are relatively straightforward to transport to hard-to-reach territories and are easy to administer without the need for cold-storage or injections.” Fighting More Than EBOV In addition to EBOV, RedHill said opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants and several other viruses, including Influenza A. Opaganib is currently also in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, acute respiratory distress syndrome (ARDS) and radiological and chemical protection or mitigation. RedHill Biopharma’s novel drug has also been selected for evaluation by other NIH-funded U.S. government countermeasure programs including the Radiation and Nuclear Countermeasures Program (RNCP) for development as a potential treatment for Acute Radiation Syndrome (ARS) and by the BARDA Chemical Medical Countermeasures (Chem MCM) Program and the NIH/NIAID Chemical Countermeasures Research Program (CCRP), in addition to several other U.S. government and non-government collaborations. Ebola is a fast-spreading and often deadly disease that needs better solutions. RedHill Biopharma and BARDA are betting on opaganib to potentially provide another easier-to-mobilize option to fight outbreaks. To learn more about RedHill Biopharma’s novel drug, click here. Featured photo by CDC on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 15, 2024 09:00 AM Eastern Daylight Time

Image

AmeriLife's MCC Brokerage Strengthens Market Position with Diversity Insurance Agency Partnership

AmeriLife

MCC Brokerage, an innovative field marketing organization in the life and health insurance industry and affiliate partner of AmeriLife Group, LLC, today announced that it has partnered with Diversity Insurance Agency, a Medicare Advantage brokerage company with more than 900 contracted agents licensed in nearly all 50 U.S. states. Per the agreement, terms of the deal were not disclosed. “We are excited to welcome Tim Barlow and his team to our growing Health Distribution network,” said Darren Houck, President of MCC Brokerage. “Diversity Insurance has set itself apart from other agencies through its hands-on approach to training, lead programs, and expert support staff, and we are confident in its continued success.” By meeting people where they are, investing in them, and nurturing their growth, Diversity Insurance Agency provides its agents with the tools and training needed to succeed. Powered by a grassroots approach, a mature outreach program of specialized community events, and a traditional door-to-door educational initiative, licensed agents guide their clients through coverage that meets their personal health and financial needs. “Securing the proper Medicare coverage can be a complex, overwhelming task for many beneficiaries,” said Tim Barlow, President of Diversity Insurance Agency. “Our personalized approach and training protocols ensure that agents are well-versed in plan offerings available in each community we serve and are trained to help consumers balance the costs and benefits to meet their needs. We are thrilled to continue this level of service with the MCC Brokerage team and AmeriLife’s distribution and partnership platform.” With MCC Brokerage and AmeriLife, DIA will enjoy expanded access to tools and resources to boost its reach, productivity, and profitability. "Tim and his team have taken traditional, person-to-person relationship-building to the next level," said Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. "This approach is vital to building trust with our customers, validates the importance of health insurance agents' role in the insurance process, and reflects an important segment of AmeriLife’s core, value-based belief in how we conduct our business." ### About Diversity Insurance Agency With headquarters in Saline, Michigan, Diversity Insurance Agency takes pride in its extensive agent training program, creating expert consumer journeys when seeking comprehensive consultation and personalized health insurance recommendations. Our agents live in the communities they serve. They are well-versed in all plan offerings they provide and are trained to assist with presenting all available options and customizations based on the individual's particular life journey. For more information, visit www.diversityins.com. About MCC Brokerage As an award-winning, innovative, and passionate field marketing organization in the life and health insurance industry, MCC Brokerage embodies a collaboration versus competition mindset, empowering agents to grow their businesses. We aim to assist agents in creating their most robust business possible, utilizing over 50 collective years of expertise. We strive to support our agents’ endeavors through building lasting relationships and unmatched customer service. For more information, visit www.mccbrokerage.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents, financial professionals, and over 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details Jeff Maldonado media@amerilife.com Partnership Inquiries Alex Hyer corporatedevelopment@amerilife.com Company Website https://amerilife.com/

October 15, 2024 09:00 AM Eastern Daylight Time

This Company Is Saving Lives With Personal Emergency Response Systems

Benzinga

By Johnny Rice, Benzinga Chia-Lin Simmons, CEO of LogicMark (NASDAQ: LGMK), was recently interviewed by Benzinga. LogicMark is a cutting-edge provider of personal emergency response systems (PERS), health communications devices and IoT technologies. CEO Chia-Lin Simmons spoke about the company and its growth strategies aimed at increasing shareholder value. She discussed her efforts to turn the company around, shifting from a one-time purchase hardware model to a SAAS and recurring revenue model. Additionally, she talked about LogicMark’s expansion into personal safety, not just for aging adults but for all. Watch the full interview here: Featured photo by Piotr Chrobot on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 14, 2024 09:15 AM Eastern Daylight Time

Video Image

News Release

Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges

KAPA

The global oncology landscape is on the brink of transformation, with cancer cases expected to rise sharply, particularly in lower-income countries, where the number of new cases could soar to 32 million annually by 2050. This growing demand for cancer treatments has driven global spending on oncology medicines to $223 billion in 2023, with a projected increase to $409 billion by 2028. The launch of 25 novel oncology drugs in 2023, along with over 2,000 new clinical trials, highlights a dynamic period of innovation in the sector. Breakthrough therapies, including cell and gene therapies, antibody-drug conjugates, and radioligand treatments, show significant promise but remain unevenly accessible. As oncology treatments continue to evolve at a rapid pace, this environment presents a unique window of opportunity for investors to explore emerging biopharma companies, which are positioned to lead the charge in addressing unmet medical needs in cancer care. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, is steadily building a presence in the oncology space. Focusing on therapies aimed at overcoming cancer drug resistance and immune suppression, Kairos has developed a promising pipeline that could attract attention. Among its most notable candidates is ENV105, a therapy designed to target the mechanisms that allow tumors to evade treatment. With ongoing clinical trials and a recent IPO, Kairos Pharma (KAPA) shows potential as an emerging player in biotechnology, particularly as it continues to develop personalized cancer treatments. Exploring New Avenues in Cancer Treatment with ENV105 At the forefront of Kairos Pharma's mission is ENV105, a groundbreaking therapy aimed at reversing drug resistance in cancer patients. This drug distinguishes itself from traditional treatments by targeting the mechanisms that allow tumors to evade existing therapies. Mechanism of Action: ENV105 works by inhibiting the CD105 protein, which plays a critical role in the Bone Morphogenetic Protein (BMP) pathway. Unlike many cancer treatments that focus on blocking Tumor Necrosis Factor (TNF), ENV105 addresses the BMP pathway, which can contribute to increased tumor resistance. By disrupting this pathway, ENV105 enhances the effectiveness of existing cancer treatments. Biomarker Advantage: A significant aspect of ENV105 is its associated biomarker, which can predict patient responses before treatment begins. This capability allows for a more personalized approach, ensuring that patients who are most likely to benefit from the therapy are identified upfront, potentially increasing treatment success rates. Clinical Trial Successes The results from recent clinical trials are promising. In studies involving ENV105, 62% of patients experienced disease stabilization or regression after just two months of treatment—a remarkable outcome compared to the typical response rates seen in similar populations. Additionally, ENV105 has shown efficacy in enhancing the effects of existing therapies for both prostate and lung cancers, two of the most prevalent cancer types. Recent Developments and Partnerships Kairos Pharma is making significant strides in its clinical trials. The company recently dosed its first patients in a Phase 1 trial combining ENV105 with osimertinib for non-small cell lung cancer. This trial aims to evaluate the safety and tolerability of the combination, while a concurrent Phase 2 trial tests ENV105 alongside apalutamide for treating castrate-resistant prostate cancer. John Yu, CEO of Kairos Pharma, emphasizes the company’s commitment to addressing urgent medical needs: “The initiation of these trials speaks to the dedication of the Kairos team to develop therapies for today’s unmet medical needs.” Further enhancing its prospects, Kairos Pharma has partnered with PreCheck Health Services to develop companion biomarkers that will identify which patients are most likely to benefit from ENV105. This collaboration aims to incorporate advanced molecular diagnostics into clinical practice, allowing for better patient selection and monitoring. On September 16, 2024, Kairos Pharma made its debut on the NYSE American under the ticker symbol “KAPA,” successfully raising $6.2 million through its initial public offering. The proceeds will be vital for funding ongoing clinical trials and advancing its diverse pipeline, which includes ENV105 and other innovative candidates like KROS 101. Conclusion With its focus on reversing cancer drug resistance and improving immune response, KAPA is poised to make an impact in oncology. As Kairos Pharma continues to advance its trials and develop personalized cancer therapies, it stands on the brink of potentially revolutionizing cancer treatment. For those looking to invest in a company with a bright future in biotechnology, Kairos Pharma is one for the watchlist. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

October 14, 2024 06:00 AM Eastern Daylight Time

MedCognetics Introduces the First Embedded AI Cancer Detection System for Mammography Imaging

MedCognetics

MedCognetics, Inc., a company focusing on medical imaging AI, today announced the successful testing and implementation of the first embedded AI image processing and cancer detection system for mammography. The system utilizes the NVIDIA IGX Orin TM medical-grade edge AI platform alongside MedCognetics’ advanced AI-enabled software, CogNet AI-MT, which was developed in collaboration with clinical leaders worldwide. CogNet AI-MT has been trained on a diverse global dataset to enhance the performance of radiologists and help improve patient outcomes worldwide. Incorporating MedCognetics’ new system would allow for AI-driven image enhancement and cancer detection to occur in real-time within the mammography device itself. The embedded solution eliminates latency, delivering immediate, high-quality image analysis, a significant improvement over traditional setups that require external workstations or cloud-based processing. This approach is poised to improve patient outcomes through faster results, enhanced image quality and reduced hardware costs. “Embedding our CogNet AI-MT software directly into mammography imaging equipment means we can enhance image quality and provide immediate cancer detection without the need for costly hardware upgrades,” said Debasish “Ron” Nag, CEO of MedCognetics. “Using the NVIDIA IGX platform, we’re advancing medical imaging technology, making high-quality diagnostic tools more accessible to radiologists and imaging centers around the world.” The NVIDIA IGX Orin platform combines enterprise-level hardware, software, and support. It is purpose-built for industrial and medical edge computing. The platform delivers the performance, durability, security, and safety required for advanced AI applications and features programmable safety extensions, commercial OS support, and powerful AI software. These capabilities, equip organizations to confidently deploy AI safely and securely for enhanced human and machine collaboration. The embedded AI system developed by MedCognetics offers several key benefits: On-Premises Device: Rapid, complete analysis right in the radiology workflow. Enhanced Image Quality: AI-driven enhancements improve the clarity and detail of images without requiring high-end, expensive hardware. Immediate Results: Processing occurs within the device, providing instant analysis and reducing the wait time for results. Cost Efficiency: Medical device manufacturers can achieve high-end image quality at a fraction of the cost by utilizing AI rather than upgrading hardware. Workflow Optimization: Enables worklist prioritization and clinic-determined workflow optimization, enhancing the accuracy and efficiency of radiologists and imaging centers. Easy Upgrades and Maintenance: Software-based solutions are easier to update and maintain, helping to ensure that medical imaging equipment remains cutting-edge without frequent hardware replacements. Earlier this year, MedCognetics was awarded a groundbreaking patent by the United States Patent and Trademark Office (USPTO) for its inclusive, unbiased medical imaging AI technology in mammography. Its expertise in embedded engineering, combined with the NVIDIA IGX platform, is poised to significantly advance medical imaging technology. This work underscores the importance of integrating AI into medical devices to enhance diagnostic capabilities and patient care. For more information about this new embedded AI cancer detection system, visit here. About CogNet AI-MT® CogNet AI-MT is part of MedCognetics' comprehensive CogNet AI™ platform, designed to enhance radiologists' capabilities by expanding insights and awareness in medical imaging. This unbiased platform, trained on a diverse global dataset, advances the performance of radiologists and imaging centers, delivering accurate care for patients worldwide. CogNet AI-MT employs advanced AI and Machine Learning (ML) to detect early signs of cancer across all ethnicities and can be deployed on customer premises, in the cloud, or via the web. The platform is FDA 510(k) cleared for triage of mammogram images. Useful Links: Learn More: www.medcognetics.com Follow us: X | LinkedIn Sales and Partnership Inquiries: Please contact MedCognetics, Inc. at: media@medcognetics.com About MedCognetics, Inc. MedCognetics provides an advanced AI software platform that integrates into radiology workflow. In addition, the AI algorithm is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating a more predictable medical outcome and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com. # # # Contact Details ANW Networks Alicia Nieva-Woodgate +1 415-515-0866 alicia@anwnetworks.com Company Website https://www.medcognetics.com

October 10, 2024 11:15 AM Eastern Daylight Time

SBC Medical Group (Nasdaq: SBC) Earnings Update: H1 2024 Revenue Up 29% And Net Income Up 123%

Benzinga

By Gerelyn Terzo, Benzinga After successfully completing its business combination with Pono Capital in September, SBC Medical Group (NASDAQ: SBC) has been trading on the Nasdaq under the symbol “SBC”, marking a key moment in its transition as a global company The listing on the Nasdaq is expected to provide SBC Medical with access to capital while bolstering its partnership opportunities and paving the way for an expansion in the U.S. and South Asian markets. Tokyo-based SBC Medical has already gained a reputation as a go-to medical services company specializing in the aesthetic medical industry. After paving the way in Japan, where it reports it has built the biggest network of franchised clinics in the country, SBC Medical has now set its sights on an international expansion, including the broader South Asian and U.S. markets, where it intends to maintain the high standards which drove its growth in Japan. Led by renowned industry executive Dr. Yoshiyuki Aikawa, SBC Medical seems to have the wind at its back, as evidenced by a strengthening balance sheet in H1 2024. Despite economic headwinds, the company continued to grow its available cash in the period in excess of $115 million on a pro forma combined basis while also managing to increase net income more than twofold year-over-year and growing revenue while honing expenses. SBC Medical’s Financial Performance In H1 2024, SBC Medical reported revenue of $107.9 million, an increase of 28.6% compared to $83.9 million in the first half of 2023. SBC Medical more than doubled its net income to $37.2 million from $16.6 million in H1 2023. Growth Opportunities In Japan Given SBC Medical’s performance so far in 2024, the company has set its sights on further growth opportunities, particularly in Japan, where it says it already enjoys a competitive advantage. SBC recognizes an opportunity for further growth there as it continues to solve some critical pain points for doctors, allowing physicians to focus on their patients. SBC Medical’s fully digitized integrated system streamlines processes like customer flow and human resources, while its educational system offers a quality patient experience at its franchisees. Additionally, SBC’s extensive network of franchise clinics empowers doctors to hone their skill sets in diverse medical treatments. As for its expansion, SBC Medical is targeting adjacent areas such as fertility treatments, hair loss solutions and online clinic services, all of which present robust growth and profit potential. The company believes its reputation should pave the way for strategic business-to-business partnerships to accelerate growth. SBC Medical seems well-positioned to capitalize on these opportunities with its strong balance sheet. With its recent listing, SBC Medical’s growth story is just getting underway. Investors who are interested in taking a front seat to the action can learn more about the company here. Featured photos courtesy of SBC Medical Group. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2024 08:30 AM Eastern Daylight Time

Image

AGC Biologics Begins Operations at New State-of-the-Art Manufacturing Building in Copenhagen after Successful Inspection and Licensing from Danish Medicines Agency

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today the successful completion of the final milestone at its new manufacturing building at its Copenhagen site. The site received authorization and a license to begin production from the Danish Medicines Agency for its new four-story 19,000 m² manufacturing building in September, allowing it to begin official operations. AGC Biologics started production on its first project at the new building shortly after approval, a phase II/III clinical project. The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors, two complementary downstream suites, and dedicated warehouse and quality control laboratory spaces. The new building has doubled the capacity for mammalian manufacturing at the AGC Biologics Copenhagen manufacturing plant. “Getting operational approval from the Danish Medicines Agency was the final step in a three-year journey that many individuals have contributed to, and this milestone is one we were proud to celebrate as a site” said Andrea Porchia, General Manager of the Copenhagen site. “We now begin the work of producing more treatments at this facility than ever before and believe this is one of the best locations for developer partners seeking CDMO services in Europe.” AGC Biologics Copenhagen has an extensive operational track record and expertise spanning early-stage development through clinical and commercial manufacturing. It operates and supports drug substance projects using both mammalian and microbial systems and has produced seven commercial products. To learn more about AGC Biologics’ protein biologics manufacturing site in Copenhagen, visit https://www.agcbio.com/facilities/copenhagen. For more information on the company’s end-to-end global CDMO services in the U.S., Europe, and Japan, visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

October 10, 2024 12:07 AM Mountain Daylight Time

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

1 2 3 4 5 6 ... 302